MiR30‐GALNT1/2 Axis‐Mediated Glycosylation Contributes to the Increased Secretion of Inactive Human Prohormone for Brain Natriuretic Peptide (proBNP) From Failing Hearts

Background Recent studies have shown that plasma levels of the biologically inactive prohormone for brain natriuretic peptide (proBNP) are increased in patients with heart failure. This can contribute to a reduction in the effectiveness of circulating BNP and exacerbate heart failure progression. The precise mechanisms governing the increase in proBNP remain unclear, however. Methods and Results We used our recently developed, highly sensitive human proBNP assay system to investigate the mechanisms underlying the increase in plasma proBNP levels. We divided 53 consecutive patients hospitalized with heart failure into 2 groups based on their aortic plasma levels of immunoreactive BNP. Patients with higher levels exhibited more severe heart failure, a higher proportion of proBNP among the immunoreactive BNP forms secreted from failing hearts, and a weaker effect of BNP as estimated from the ratio of plasma cyclic guanosine monophosphate levels to log‐transformed plasma BNP levels. Glycosylation at threonines 48 and 71 of human proBNP contributed to the increased secretion of proBNP by attenuating its processing, and GalNAc‐transferase (GALNT) 1 and 2 mediated the glycosylation‐regulated increase in cardiac human proBNP secretion. Cardiac GALNT1 and 2 expression was suppressed by microRNA (miR)‐30, which is abundantly expressed in the myocardium of healthy hearts, but is suppressed in failing hearts. Conclusions We have elucidated a novel miR‐30‐GALNT1/2 axis whose dysregulation increases the proportion of inactive proBNP secreted by the heart and impairs the compensatory actions of BNP during the progression of heart failure.

[1]  K. Nakao,et al.  Pro-B-type natriuretic peptide is cleaved intracellularly: impact of distance between O-glycosylation and cleavage sites. , 2015, American journal of physiology. Regulatory, integrative and comparative physiology.

[2]  Takeshi Kimura,et al.  Branched-chain amino acids ameliorate heart failure with cardiac cachexia in rats. , 2015, Life sciences.

[3]  Akshay S. Desai,et al.  Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure , 2015, Circulation.

[4]  A. Mebazaa,et al.  Post-translational modifications enhance NT-proBNP and BNP production in acute decompensated heart failure. , 2014, European heart journal.

[5]  J. Burnett,et al.  Pro–B-Type Natriuretic Peptide-1-108 Processing and Degradation in Human Heart Failure , 2014, Circulation. Heart failure.

[6]  Teruo Okano,et al.  Human iPS cell-engineered cardiac tissue sheets with cardiomyocytes and vascular cells for cardiac regeneration , 2014, Scientific Reports.

[7]  M. Goumans,et al.  The microRNA-15 family inhibits the TGFβ-pathway in the heart. , 2014, Cardiovascular research.

[8]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[9]  I. Masuda,et al.  Direct Immunochemiluminescent Assay for proBNP and Total BNP in Human Plasma proBNP and Total BNP Levels in Normal and Heart Failure , 2013, PloS one.

[10]  Shi-ming Liu,et al.  MiR-30-Regulated Autophagy Mediates Angiotensin II-Induced Myocardial Hypertrophy , 2013, PloS one.

[11]  Henrik Clausen,et al.  Site-specific protein O-glycosylation modulates proprotein processing - deciphering specific functions of the large polypeptide GalNAc-transferase gene family. , 2012, Biochimica et biophysica acta.

[12]  K. Nakao,et al.  Complexity of molecular forms of B-type natriuretic peptide in heart failure , 2012, Heart.

[13]  Lawrence A Tabak,et al.  Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family. , 2012, Glycobiology.

[14]  S. Brunak,et al.  A Systematic Study of Site-specific GalNAc-type O-Glycosylation Modulating Proprotein Convertase Processing* , 2011, The Journal of Biological Chemistry.

[15]  L. R. Potter,et al.  ProBNP(1-108) is resistant to degradation and activates guanylyl cyclase-A with reduced potency. , 2011, Clinical chemistry.

[16]  Shinya Yamanaka,et al.  Efficient and Scalable Purification of Cardiomyocytes from Human Embryonic and Induced Pluripotent Stem Cells by VCAM1 Surface Expression , 2011, PloS one.

[17]  Xue-Long Sun,et al.  Glycosylation and processing of pro-B-type natriuretic peptide in cardiomyocytes. , 2011, Biochemical and biophysical research communications.

[18]  J. Zavadil,et al.  miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. , 2011, Cancer cell.

[19]  Yasuko Matsumura,et al.  A more efficient method to generate integration-free human iPS cells , 2011, Nature Methods.

[20]  K. Nakao,et al.  Current biochemistry, molecular biology, and clinical relevance of natriuretic peptides. , 2011, Journal of cardiology.

[21]  T. Soga,et al.  Analysis of Metabolic Remodeling in Compensated Left Ventricular Hypertrophy and Heart Failure , 2010, Circulation. Heart failure.

[22]  S. Menon,et al.  Clinical Implications of Defective B‐Type Natriuretic Peptide , 2009, Clinical cardiology.

[23]  E. Shin,et al.  Acute Myocardial Infaction with Simultaneous ST‐segment Elevation in the Precordial and Inferior Leads due to Unusually Very Long LAD Extended to Posterior Wall of LV , 2009, Clinical cardiology.

[24]  A. G. Semenov,et al.  Processing of pro-brain natriuretic peptide is suppressed by O-glycosylation in the region close to the cleavage site. , 2009, Clinical chemistry.

[25]  M. Redfield,et al.  Immunoreactivity and Guanosine 3′,5′-Cyclic Monophosphate Activating Actions of Various Molecular Forms of Human B-Type Natriuretic Peptide , 2007, Hypertension.

[26]  Faquan Liang,et al.  Evidence for functional heterogeneity of circulating B-type natriuretic peptide. , 2007, Journal of the American College of Cardiology.

[27]  N. S. Pollitt,et al.  The precursor to B-type natriuretic peptide is an O-linked glycoprotein. , 2006, Archives of biochemistry and biophysics.

[28]  T. Strom,et al.  Polypeptide GalNAc-transferase T3 and Familial Tumoral Calcinosis , 2006, Journal of Biological Chemistry.

[29]  C. Granier,et al.  Assay for measurement of intact B-type natriuretic peptide prohormone in blood. , 2006, Clinical chemistry.

[30]  D. Behar,et al.  Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis , 2004, Nature Genetics.

[31]  K. Nakao,et al.  NRSF regulates the fetal cardiac gene program and maintains normal cardiac structure and function , 2003, The EMBO journal.

[32]  D. Fukai,et al.  Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. , 1997, Circulation.

[33]  S Sasayama,et al.  Transition from compensatory hypertrophy to dilated, failing left ventricles in Dahl salt-sensitive rats. , 1994, The American journal of physiology.

[34]  K. Kugiyama,et al.  Localization and Mechanism of Secretion of B‐Type Natriuretic Peptide in Comparison With Those of A‐Type Natriuretic Peptide in Normal Subjects and Patients With Heart Failure , 1994, Circulation.

[35]  Naoto Minamino,et al.  A new natriuretic peptide in porcine brain , 1988, Nature.

[36]  R. Duisters,et al.  MIRNA-133 AND MIRNA-30 REGULATE CONNECTIVE TISSUE GROWTH FACTOR: IMPLICATIONS FOR A ROLE OF MIRNAS IN MYOCARDIAL MATRIX REMODELING , 2013 .

[37]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.